ModMed Acquisition, Valuation, Funding & Investors

ModMed was acquired by Clearlake Capital for $10B in March 2025.

ModMed acquisition price

$10B

Acquired by Clearlake Capital · Mar 2025

ModMed revenue

$50M

Undisclosed stage · May 2017

Cumulative funding ModMed raised

$456M

across 7 funding rounds

Key investors in ModMed

  • Summit Partners
  • Pentland Brands
  • Warburg Pincus
  • CPP Investments
  • Sands Capital Ventures
  • IBM

ModMed Overview

About ModMed

ModMed is a Boca Raton-headquartered developer of cloud-based electronic health record systems for specialty medical practices. Its platforms include ophthalmology, orthopedics, and dermatology-specific EHR, practice management, and revenue cycle management tools built with input from practicing physicians. Serving over 3,000 practices nationwide, ModMed processes billions in claims annually through its fully integrated suite. The company expanded into pain management and gastroenterology solutions in recent years.


Founded

2010

HQ

United StatesBoca Raton, FL

Website

modmed.com

Status

Acquired

Customer focus

B2B

Revenue model

Subscription

Revenue

$50M (May 2017)

Valuation

$962M (May 2017)

ModMed Acquisition

ModMed was acquired by Clearlake Capital for $10B on 3 March 2025.

Before the acquisition ModMed had raised $456M across 7 funding rounds.

ModMed, a Boca Raton-based pioneer in specialty-specific healthcare SaaS technology, develops cloud-based electronic health records (EHR), practice management, revenue cycle management (RCM), patient engagement, payment processing, and native AI integrations tailored for ambulatory physician practices across medical specialties. Clearlake Capital Group, a Santa Monica-headquartered private equity firm with over $90 billion in assets under management and a focus on technology and healthcare investments, acquired a significant majority stake from Warburg Pincus, which had held the stake since 2017, valuing ModMed at $5.3 billion. Summit Partners and ModMed co-founders Daniel Cane and Michael Sherling retained minority shares, while previous investors included Pentland Capital. The deal was announced on March 3, 2025, amid a sluggish private equity market influenced by inflation and high interest rates that delayed 4,000 to 6,500 exits, positioning this as an early 2025 transaction following ModMed's January auction seeking over $5 billion after prior sale considerations since 2022. Strategic rationale centers on Clearlake's track record in scaling software and healthcare tech platforms to accelerate ModMed's growth, innovation in AI-powered solutions, product investments, and customer experiences, with co-CEOs Daniel Cane and Joe Harpaz (appointed 2024) emphasizing alignment on transforming patient-provider interactions. The transaction, advised by Sidley for Clearlake and Kirkland & Ellis for ModMed, closed on April 30, 2025, subject to regulatory approvals. ModMed's selection of Clearlake reflects confidence in its growth-driving expertise, enabling expansion of its robust AI roadmap and leadership in ambulatory healthcare software amid rising demand across specialties.

ModMed acquisition details
AcquirerDateTypePrice
  • Clearlake Capital
3 Mar 2025PE buyout$10B

ModMed Valuation

ModMed is currently valued at $962M, based on its undisclosed-stage round in May 2017.

The $231M round was led by Warburg Pincus.

ModMed's valuation has grown 5.3x from $181M at its Series C in August 2013 to $962M in May 2017, across 2 priced rounds.

ModMed valuation by funding round

Revenue multiple
ModMed valuation by funding round
DateStageValuationRevenue Multiple
May 2017Undisclosed stage$962M19.2x
Aug 2013Series C$181M-

ModMed Revenue

ModMed's latest recorded revenue is $50M, as of its undisclosed-stage round in May 2017. At a $962M valuation, that implies a 19.2x revenue multiple.

ModMed revenue by funding round

ModMed revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
May 2017$50M$962M19.2xUndisclosed stage

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

ModMed Funding History

ModMed has raised a total of $456M across 7 funding rounds.

ModMed's first fundraising round was a $14M Series C in August 2013. The most recent completed round was a $100M undisclosed-stage round in April 2025.

ModMed funding rounds

ModMed funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Apr 2025Undisclosed stageCPP Investments$100M-ModMed is a leading provider of specialty-specific SaaS solutions for ambulatory medical practices. CPP Investments invested US$100 million in ModMed alongside Clearlake Capital, as reported in their Q1 FY2026 (June 30, 2025) and Q2 FY2026 (September 30, 2025) net asset updates. This appears to be part of a growth investment, consistent with a prior significant majority growth investment from Clearlake Capital highlighted in ModMed's press release, though investor details in that release focus on Clearlake without mentioning CPP. The investment supports ModMed's position in healthcare SaaS, targeting mission-critical cloud-native products for medical specialties with resilient demand and growth. Clearlake has a history of HCIT investments including ModMed, with over $90 billion in assets under management and focus on technology and healthcare intersections.
Feb 2022Undisclosed stage-$53M-ModMed (Modernizing Medicine) is a leader in specialty-specific healthcare SaaS technology, providing cloud-based electronic health records and AI-powered medical practice platforms focused on ambulatory care across medical specialties. The company has raised approximately $53 million in its most recent funding round on or around February 22, 2022, listed as a Series F extension with $30-53 million, following prior rounds including a $231 million Series F in 2017 at $1 billion valuation. This 2022 round aligns with total funding figures of $340 million over 10-11 rounds from investors like Warburg Pincus. Post-2022 developments include Warburg Pincus selling a majority stake to Clearlake Capital in 2025 at a $5.3 billion valuation, recognizing ModMed's growth in AI-enabled documentation, workflow streamlining, and resilient demand in healthcare IT. Earlier, a 2017 Series F valued the company at $1 billion. ModMed emphasizes innovation at the healthcare-technology intersection, with Clearlake's investment aimed at accelerating expansion and patient-provider experience transformation.
May 2017Undisclosed stageWarburg Pincus (lead)$231M$962MModernizing Medicine is a specialty-specific health information technology company that develops electronic health record and practice management solutions for surgical and medical specialties. The company delivers software platforms designed to help healthcare practices create, consume, and utilize clinical and administrative information to improve efficiency and patient outcomes. In May 2017, Warburg Pincus, a leading global private equity firm, made a $231 million equity investment into ModMed to provide liquidity to existing shareholders, fund expansion, and support strategic initiatives. This investment valued the company at approximately $962 million on a post-money basis. The capital infusion was intended to support automation of prior authorization workflows, deployment of an eCommerce platform, investment in data exchange and reconciliation capabilities, and expansion of telemedicine access. CEO Daniel Cane noted that Warburg Pincus brought deep healthcare technology sector experience to support ModMed's mission of transforming healthcare information management and outcomes.
Sep 2015Series EPentland Brands; Sands Capital Ventures; Summit Partners$38M-ModMed, formerly Modernizing Medicine, develops the Electronic Medical Assistant (EMA), a cloud-based, specialty-specific electronic medical record (EMR) system built by physicians for specialties including dermatology, ophthalmology, orthopedics, otolaryngology, gastroenterology, urology, and plastic surgery. Available as a native iPad app and web-enabled, EMA adapts to providers' styles and supports ICD-10. The company also offers billing, inventory management, endoscopy reporting, practice management, patient portals, data analytics, and revenue cycle management. In September 2015, it closed a $38 million Series E round from Pentland Group, Summit Partners, and Sands Capital Ventures, bringing total funding to about $87 million. This followed a $14 million round and the acquisition of g-Med, capturing 18% of the gastroenterology market, with recent entry into urology. The Series E funding supported growth in the specialty-specific provider market, highlighted by four No. 1 EHR Black Book Rankings in dermatology, orthopedics, otolaryngology, and gastroenterology. EMA was used by over 9,000 providers across the US and territories at the time. CEO Daniel Cane emphasized opportunities to improve physician efficiencies and patient outcomes. Post-2015, ModMed expanded offerings like mobile patient engagement, e-commerce, telemedicine, and prior authorization tools, including a schema app with IBM Watson. By around 2017, it reportedly crossed $100 million in annual subscription-based revenue, with total funding reaching $332.6 million before a $231 million round in May 2017 at $1B valuation. Later developments included further funding and a 2025 acquisition-financing.
Mar 2015Series AIBM (lead)$5M-Modernizing Medicine, known as ModMed, develops cloud-based, specialty-specific electronic medical records (EMR) systems like the Electronic Medical Assistant (EMA), along with billing, revenue, and inventory management solutions for physicians. Thousands of specialty physician practices in the U.S. used its technology as of March 2015. The company focuses on eight medical specialties, including dermatology, and integrates cognitive computing via apps like schEMA powered by IBM Watson for point-of-care clinical decision support. On March 19, 2015, IBM invested in Modernizing Medicine as part of its $100 million Watson innovation fund, capping a $20 million Series D round that brought total funding to $49 million. Funds supported market expansion, solution enhancements, and schEMA development leveraging Watson to analyze medical data for evidence-based medicine. Post-2015, Modernizing Medicine raised additional rounds, including $38 million in September 2015 Series E from Pentland Group, Summit Partners, and Sands Capital Ventures, reaching over $87 million total by 2017, followed by $231 million from Warburg Pincus.
Nov 2014Series DPentland Brands (lead); Summit Partners (lead)$15M-Modernizing Medicine, known as ModMed, is a medical technology company founded in 2010 that provides electronic medical record (EMR) systems, revenue cycle management, and telehealth solutions. The company had raised a total of USD 87 million across at least five funding rounds prior to a later USD 231 million raise from Warburg Pincus, with prior investors including Pentland Group, Summit Partners, IBM, and Sands Capital Ventures. In 2014, around the time of the funding from Pentland Brands and Summit Partners, ModMed generated USD 30.5 million in revenue. By 2015, revenue grew to more than USD 50 million, and by the end of 2016, the company achieved a mostly recurring revenue run rate exceeding USD 100 million. Modernizing Medicine became EBITDA-positive in 2016 but shifted to reinvesting profits for growth, targeting 35%-40% annual organic growth. Industry multiples at the time were approximately 1x for perpetual revenue, 3x-5x for transactional revenue, and 5x-7x for recurring subscription revenue, though not specifically tied to ModMed's valuation.
Aug 2013Series CSummit Partners (lead)$14M$181MModernizing Medicine, known as ModMed, develops the Electronic Medical Assistant (EMA), a cloud-based specialty-specific electronic medical record (EMR) system. The company raised $14 million in its Series C funding round on August 20, 2013, from Summit Partners. This investment supported the company's growth in the healthcare technology sector, focusing on specialty practices. At the time of the Series C round, Modernizing Medicine had gained recognition for its market traction, including phenomenal customer reviews and meaningful use attestations for EMA. The company was listed at No. 47 on Forbes’ annual ranking of America’s Most Promising Companies and recognized by Modern Healthcare as one of the 2013 Best Places to Work in Healthcare. The post-money valuation for the round was $181.32 million. Summit Partners, a growth equity firm, led the investment, highlighting EMA’s strength in technology and market position. Modernizing Medicine continued to expand, serving multiple medical specialties and achieving accolades as South Florida Business Journal’s #1 Fastest Growing Company.

Who has invested in ModMed?

6 investors have backed ModMed across its funding rounds, including Summit Partners, Pentland Brands, Warburg Pincus, CPP Investments, Sands Capital Ventures and IBM.

Lead investors include Warburg Pincus, IBM, Pentland Brands and Summit Partners.


ModMed Investors

Investors in ModMed by funding rounds participated
InvestorHQRoundsRoleFirst check
Summit PartnersUnited StatesBoston, MA3LeadAug 2013
Pentland BrandsUnited KingdomLondon2LeadNov 2014
Sands Capital VenturesUnited StatesWashington, DC1ParticipantSep 2015
CPP InvestmentsCanadaToronto1ParticipantApr 2025

This data is available for Pro users. Sign up to see all 6 ModMed investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by ModMed

ModMed has acquired 7 companies to date.

Last acquisition by ModMed was on April 19th 2026. ModMed acquired Bonsai Health for undisclosed valuation.


Latest Acquisitions by ModMed

Bonsai Health
Xtract Solutions
Klara
TRAKnet
Description
Bonsai Health is a U.S.-based AI healthcare platform reducing administrative burdens for providers. The company deploys tools for clinical documentation, patient triage, and workflow automation, improving outcomes in hospitals and clinics nationwide through integrations with electronic health records systems.
Xtract Solutions is a software developer focused on healthcare safety tools preventing medication errors from incorrect syringe injections. Its platform uses computer vision and RFID to verify drug labels, dosages, and patient matches at point-of-care in hospitals and clinics across North America.
Klara is a patient engagement platform headquartered in Nashville, Tennessee, used by thousands of healthcare practices across 40 specialties. The software handles communications, telehealth, team collaboration, and front-desk automation, streamlining workflows from appointment scheduling to follow-ups for U.S. providers.
TRAKnet is a product from NEMO Health, a podiatrist-led firm offering practice management software for medical offices. The platform streamlines scheduling, billing, electronic health records, and patient communications to enhance efficiency in podiatry and multi-specialty clinics. TRAKnet integrates with clearinghouses for insurance claims and supports growth in competitive healthcare settings across the United States.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Los Angeles, CA
Portland, OR
New York City, NY
Detroit, MI
Deal Date19 Apr 20265 Jan 20238 Feb 202216 Apr 2021
Valuationundisclosedundisclosed$200Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all ModMed acquisitions and their M&A valuation multiples.

Start Free Trial

ModMed Competitors

ModMed competitors include listed companies like Waystar and B-Soft Co., and private ones like Commure, Doctolib, Abridge and Shanghai LinkedCare Information Technology.

Public and private companies comparable to ModMed
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
CommureUnited StatesSan Francisco, CAPrivate$200M-$7B35.0x
DoctolibFranceParisPrivate$400M-$6.4B16.0x
AbridgeUnited StatesPittsburgh, PAPrivate$117M-$5.3B45.3x
WaystarUnited StatesUnited StatesPublicly listed$1.1B$390M$5.1B5.2x
Shanghai LinkedCare Information TechnologyChinaShanghaiPrivate--$1.5B-
B-Soft Co.ChinaChinaPublicly listed$157M($37M)$769M4.8x

ModMed Public Comps

ModMed is no longer listed, but its public comps include Glaukos, United Imaging, Pro Medicus, M3 Inc., ICON plc, Waystar, Doximity, CCC Intelligent Solutions, Privia Health and Tieto.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Glaukos$507M($157M)18.4x14.6x(59.6x)166.3x
United Imaging$2.1B$367M5.5x4.8x30.7x26.9x
Pro Medicus$186M$147M66.6x62.7x84.4x77.6x
M3 Inc.$2.3B$473M3.1x3.0x14.8x11.6x
ICON plc$8.3B$816M1.9x1.9x19.2x11.3x
Waystar$1.1B$390M5.8x5.2x16.3x12.3x
Doximity$645M$229M6.3x6.2x17.7x11.9x
CCC Intelligent Solutions$1.1B$238M4.8x4.5x21.5x10.8x

This data is available for Pro users. Sign up to see all ModMed competitors and their valuation data.

Start Free Trial

Common questions about ModMed

When was ModMed founded?ModMed was founded in 2010.
Where is ModMed headquartered?ModMed is headquartered in Boca Raton, FL, United States.
Is ModMed publicly listed?No, ModMed was acquired by Clearlake Capital in March 2025.
Who acquired ModMed?ModMed was acquired by Clearlake Capital in March 2025.
How much was ModMed acquired for?ModMed was acquired for $10B in March 2025.
What is ModMed's valuation?ModMed was last valued at $962M in its undisclosed-stage round in May 2017.
How much funding has ModMed raised?ModMed has raised $456M across 7 funding rounds.
What was ModMed's last funding round?ModMed's last funding round was a $100M undisclosed-stage round in April 2025.
Who are ModMed's investors?ModMed's investors include Summit Partners, Pentland Brands, Sands Capital Ventures, CPP Investments, Warburg Pincus and IBM.
What is ModMed's revenue?ModMed's latest recorded revenue is $50M (May 2017).
What is ModMed's revenue multiple?ModMed's latest valuation implies a 19.2x revenue multiple ($962M valuation on $50M of revenue).
Which companies are comparable to ModMed?Companies comparable to ModMed include Commure, Doctolib, Abridge, Waystar, Shanghai LinkedCare Information Technology and B-Soft Co..
How many companies has ModMed acquired?ModMed has acquired 7 companies, including Bonsai Health, Xtract Solutions, Klara, TRAKnet and Exscribe.
What was the largest acquisition by ModMed?The $200M acquisition of Klara in February 2022 is the largest acquisition ModMed has made to date.

See companies similar to ModMed

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial